Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Cardiovascular and neuropsychiatric risks of varenicline - Authors' reply.

Kotz D., Viechtbauer W., Simpson C., van Schayck OCP., West R., Sheikh A.

Original publication

DOI

10.1016/s2213-2600(16)00056-4

Type

Journal article

Journal

The Lancet. Respiratory medicine

Publication Date

03/2016

Volume

4

Addresses

Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany; Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, Netherlands; Allergy & Respiratory Research Group, Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK; Cancer Research UK Health Behaviour Research Centre, University College London, London, UK. Electronic address: Daniel.Kotz@med.uni-duesseldorf.de.

Keywords

Humans, Cardiovascular Diseases, Nicotinic Agonists, Mental Disorders, Female, Male, Varenicline, Tobacco Use Cessation Devices